Recent meta‐analysis and randomized clinical trials of APOC3 mRNA‐targeted therapeutics, including volanesorsen [3], plozasiran [4], and olezarsen [5], have confirmed their efficacy in both decreasing serum TG levels and lowering the risk of AP. This evidence concerns the gene APOC3 and alkaline phosphatase measurement.